Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition
Crovalimab Crovalimab: An experimental complement inhibitor C5 monoclonal antibody.
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Oral complement factor D inhibitor danicopan for paroxysmal nocturnal hemoglobinuria
Introduction: Paroxysmal nocturnal hemoglobinuria Paroxysmal nocturnal he
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria
Crovalimab Crovalimab: An experimental complement inhibitor C5 monoclonal antibody.
Aplastic Anemia, MDS, PNH Virtual Support Group-Saturdays-2024-December
AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare and serious co
Family/Caregiver Virtual Support Group - 2024 December
AAMDSIF is pleased to announce that we will host a support group for those caregiving for patients diagnosed with aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh)
Pediatric Parents Virtual Support Group - 2026 - January
This virtual support group is designed to support pediatric parents whose children have been diagnosed with aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare
Learn about PNH (Paroxysmal Nocturnal Hemoglobinuria)
Original Publication Date
Article Source
AAMDSIF Web Content
Recently, there has been increased mention of paroxysmal nocturnal hemoglobinuria (PNH) in the news and on social media. As part of our mission, the Aplastic Anemia and MDS International Foundation (AAMDSIF) works with leading PNH specialists to provide patients, their support…
Caner Saygin, MD
Institution
University of Chicago
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)